UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effectiveness of an Exercise and Educational-Based Prehabilitation Program in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy (PREOptimize) on Functional Outcomes: A Randomized Controlled Trial

Physical therapy, 2024-10

2024

Volltextzugriff (PDF)

Small Non-Coding RNAs and Their Role in Locoregional Metastasis and Outcomes in Early-Stage Breast Cancer Patients

International journal of molecular sciences, 2024-04, Vol.25 (7), p.3982

2024

Volltextzugriff (PDF)

Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy

International journal of molecular sciences, 2024-02, Vol.25 (5), p.2627

2024

Volltextzugriff (PDF)

Secreted Protein Acidic and Rich in Cysteine ( SPARC) Polymorphisms in Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer Patients

Biomedicines, 2023-12, Vol.11 (12), p.3231

2023

Volltextzugriff (PDF)

Secreted Protein Acidic and Rich in Cysteine /I Polymorphisms in Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer Patients

Biomedicines, 2023-12, Vol.11 (12)

2023

Volltextzugriff (PDF)

Prehabilitation in Patients With Breast Cancer Receiving Neoadjuvant Therapy to Minimize Musculoskeletal Postoperative Complications and Enhance Recovery (PREOPtimize): A Protocol for a Randomized Controlled Trial

Physical therapy, 2023-09, Vol.103 (9)

2023

Volltextzugriff (PDF)

Circulating miRNA Expression Is Inversely Correlated with Tumor Tissue or Sentinel Lymph Nodes in Estrogen Receptor-Positive Early Breast Cancer Patients

International journal of molecular sciences, 2023-09, Vol.24 (17), p.13293

2023

Volltextzugriff (PDF)

A Prehabilitation Program in Patients with Breast Cancer Receiving Neoadjuvant Therapy to Minimize Musculoskeletal Postoperative Complications and Enhance Recovery (PREOPtimize): A Protocol for a Randomized Controlled Trial

Physical therapy, 2023-06

2023

Volltextzugriff (PDF)

Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis

Clinical & translational oncology, 2023-04, Vol.25 (4), p.941-958

2023

Volltextzugriff (PDF)

The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic review

Clinical & translational oncology, 2023-02, Vol.25 (2), p.417-428

2023

Volltextzugriff (PDF)

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

Breast (Edinburgh), 2022-12, Vol.66, p.77-84

2022

Volltextzugriff (PDF)

The value of sentinel lymph-node biopsy after neoadjuvant therapy: an overview

Clinical & translational oncology, 2022-09, Vol.24 (9), p.1744-1754

2022

Volltextzugriff (PDF)

Ninety‐day mortality and clinical outcomes of patients with solid tumours and COVID‐19 infection during the first pandemic outbreak in Catalonia, Spain: A multicentre retrospective study

International journal of cancer, 2022-04, Vol.150 (8), p.1310-1317

2022

Volltextzugriff (PDF)

Effector Mechanisms of CD8+ HLA-DR+ T Cells in Breast Cancer Patients Who Respond to Neoadjuvant Chemotherapy

Cancers, 2021-12, Vol.13 (24), p.6167

2021

Volltextzugriff (PDF)

Associations With Definitive Outcomes and Clinical Benefit of Cancer Drugs at the Time of Marketing Approval and in the Postmarketing Period

Journal of the National Comprehensive Cancer Network, 2021-09, Vol.19 (13), p.117-125

2021

Volltextzugriff (PDF)

Circulating microRNAs in Early Breast Cancer Patients and Its Association With Lymph Node Metastases

Frontiers in oncology, 2021-08, Vol.11, p.627811-627811

2021

Volltextzugriff (PDF)

Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study

Frontiers in oncology, 2021-07, Vol.11, p.645026-645026

2021

Volltextzugriff (PDF)

Circulating leukocyte–platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents

Cancer Immunology, Immunotherapy, 2021-06, Vol.70 (6), p.1691-1704

2021

Volltextzugriff (PDF)

Overall survival, quality of life and magnitude of clinical benefit of breast cancer drugs over the last 25 years

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.6571-6571

2021

Volltextzugriff (PDF)

Treatment Response Evaluation: Science and Practice

Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology, 2021, p.3-9

2021

Volltextzugriff (PDF)

Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology

1st Edition 2021, 2021

Volltextzugriff (PDF)

MicroRNA-1291 Is Associated With Locoregional Metastases in Patients With Early-Stage Breast Cancer

Frontiers in genetics, 2020-12, Vol.11, p.562114-562114

2020

Volltextzugriff (PDF)

Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration

Cancer, 2020-10, Vol.126 (19), p.4390-4399

2020

Volltextzugriff (PDF)

Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents

Frontiers in oncology, 2020-09, Vol.10, p.1677-1677

2020

Volltextzugriff (PDF)

Factors associated with change in the magnitude of clinical benefit of anti-cancer drugs in the post-marketing period

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.7052-7052

2020

Volltextzugriff (PDF)

1 – 25 von 170

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(156)
Mit Volltextzugriff
(161)

Publikationsform

Sprache

Englisch
(165)
Spanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(119)
Life Sciences & Biomedicine
(116)
Humans
(102)
Oncology
(96)
Female
(91)
Middle Aged
(69)
Aged
(58)
Adult
(54)
Breast Cancer
(52)
Tumors
(35)
Biological And Medical Sciences
(34)
Medical Sciences
(34)
Medicine
(33)
Male
(32)
Medicine & Public Health
(31)
Breast Neoplasms - Drug Therapy
(30)
Breast Neoplasms - Pathology
(28)
Aged, 80 And Over
(25)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(25)
Treatment Outcome
(24)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Effectiveness of an Exercise and Educational-Based Prehabilitation Program in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy (PREOptimize) on Functional Outcomes: A Randomized Controlled Trial

Small Non-Coding RNAs and Their Role in Locoregional Metastasis and Outcomes in Early-Stage Breast Cancer Patients

Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy

Secreted Protein Acidic and Rich in Cysteine ( SPARC) Polymorphisms in Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer Patients

Secreted Protein Acidic and Rich in Cysteine /I Polymorphisms in Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer Patients

Prehabilitation in Patients With Breast Cancer Receiving Neoadjuvant Therapy to Minimize Musculoskeletal Postoperative Complications and Enhance Recovery (PREOPtimize): A Protocol for a Randomized Controlled Trial

Circulating miRNA Expression Is Inversely Correlated with Tumor Tissue or Sentinel Lymph Nodes in Estrogen Receptor-Positive Early Breast Cancer Patients

A Prehabilitation Program in Patients with Breast Cancer Receiving Neoadjuvant Therapy to Minimize Musculoskeletal Postoperative Complications and Enhance Recovery (PREOPtimize): A Protocol for a Randomized Controlled Trial

Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis

The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic review

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

The value of sentinel lymph-node biopsy after neoadjuvant therapy: an overview

Ninety‐day mortality and clinical outcomes of patients with solid tumours and COVID‐19 infection during the first pandemic outbreak in Catalonia, Spain: A multicentre retrospective study

Effector Mechanisms of CD8+ HLA-DR+ T Cells in Breast Cancer Patients Who Respond to Neoadjuvant Chemotherapy

Associations With Definitive Outcomes and Clinical Benefit of Cancer Drugs at the Time of Marketing Approval and in the Postmarketing Period

Circulating microRNAs in Early Breast Cancer Patients and Its Association With Lymph Node Metastases

Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study

Circulating leukocyte–platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents

Overall survival, quality of life and magnitude of clinical benefit of breast cancer drugs over the last 25 years

Treatment Response Evaluation: Science and Practice

Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology

MicroRNA-1291 Is Associated With Locoregional Metastases in Patients With Early-Stage Breast Cancer

Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration

Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents

Factors associated with change in the magnitude of clinical benefit of anti-cancer drugs in the post-marketing period

Suchergebnisse filtern